BC Selvanesan, D Chandra… - Science …, 2022 - search.ebscohost.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease. Tumors are poorly immunogenic and immunosuppressive, preventing T cell activation in the tumor …
BC Selvanesan, D Chandra… - Science …, 2022 - einstein.elsevierpure.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease. Tumors are poorly immunogenic and immunosuppressive, preventing T cell activation in the tumor …
BC Selvanesan, D Chandra… - Science Translational …, 2022 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease. Tumors are poorly immunogenic and immunosuppressive, preventing T cell activation in the tumor …
BC Selvanesan, D Chandra… - Science translational …, 2022 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease. Tumors are poorly immunogenic and immunosuppressive, preventing T cell activation in the tumor …
BC Selvanesan, D Chandra… - Science …, 2022 - researchwithrutgers.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease. Tumors are poorly immunogenic and immunosuppressive, preventing T cell activation in the tumor …
BC Selvanesan, D Chandra… - Science …, 2022 - mdanderson.elsevierpure.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease. Tumors are poorly immunogenic and immunosuppressive, preventing T cell activation in the tumor …
BC Selvanesan, D Chandra… - Science …, 2022 - pubmed.ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease. Tumors are poorly immunogenic and immunosuppressive, preventing T cell activation in the tumor …